GlassScriptPhysician profile
David N Bowers
NPI 1568494474
$40,882.94
in general payments reported to CMS, 2019-2025
43 companies · $517 in 2025
The $517 reported for 2025 was more than what 79% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,217 · 2021: $1,609 · 2022: $7,832 · 2023: $7,006 · 2024: $540 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,225 · Food and Beverage: $1,768 · Travel and Lodging: $1,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,225.00 |
| Food and Beverage | $1,768.47 |
| Travel and Lodging | $1,069.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $36,613.66 | 2019-2025 | Dysport, Iqirvo |
| Abbvie INC. | $587.42 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Radius Health, INC. | $495.51 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $404.20 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $380.66 | 2019-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $350.92 | 2019-2022 | |
| Allergan, INC. | $256.66 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $239.59 | 2019-2022 | |
| Pacira Therapeutics, INC. | $217.68 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $111.28 | 2020-2024 | Belbuca, Xtampza |
| Otsuka America Pharmaceutical, INC. | $98.69 | 2023-2025 | Nuedexta |
| Scilex Pharmaceuticals INC. | $95.40 | 2019-2022 | |
| Pfizer INC. | $87.91 | 2019-2022 | |
| Merz North America, INC. | $79.82 | 2019-2020 | |
| Tersera Therapeutics LLC | $70.33 | 2019-2025 | Prialt |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.